Stocks Health care CODX
NASDAQ · Health careCo-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. brought in $721.4K of revenue over the twelve months to June 30, 2026, down 28.1% from a year earlier. It posted a net loss of $47.1M. In fiscal 2025 capital spending exceeded operating cash flow by $29.8M. At June 30, 2026 it held $3.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Co-Diagnostics, Inc.
- Net worth
- Co-Diagnostics, Inc. has a market value (market cap) of $1.7M at the latest share price, and shareholders' equity of $12.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $622.5K (-84.1% year on year), with a net loss of $46.9M. Over the 12 months to June 30, 2026: revenue $721.4K, net loss $47.1M.
- Cash flow
- In fiscal 2025 operations used $29.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Co-Diagnostics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Co-Diagnostics, Inc. does
Co-Diagnostics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker CODX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $622.5K | -$46.9M | -$35.25 | -$29.8M |
| 2024 | $3.9M | -$37.6M | -$37.22 | -$29.9M |
| 2023 | $6.8M | -$35.3M | -$36.02 | -$23.4M |
| 2022 | $34.2M | -$14.2M | -$13.51 | $5.1M |
| 2021 | $97.9M | $36.7M | $36.92 | $40.4M |
| 2020 | $74.6M | $42.5M | $45.62 | $27.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CODX ranks in Health care
Latest SEC filings
What Co-Diagnostics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026
- September 25, 2026
- September 21, 2026Preliminary proxy statement PRE 14A
- September 16, 2026
- September 16, 2026Other event 8-K
- September 15, 2026Other event 8-K
- September 4, 2026
- September 4, 2026Additional proxy material DEFA14A
- September 4, 2026
- August 24, 2026
Insider trades
What the people running Co-Diagnostics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 23, 2026 | Serbin Richard SDirector | Received as pay | 1,695 | - |
| May 23, 2026 | Nelson James BDirector | Received as pay | 1,695 | - |
| May 23, 2026 | Egan Dwight HChief Executive Officer, Director | Received as pay | 4,584 | - |
| May 23, 2026 | Egan Dwight HChief Executive Officer, Director | Other change | 1,633 | $8.3K |
| May 23, 2026 | Murphy Edward L.Director | Received as pay | 1,695 | - |
| May 23, 2026 | Durenard EugeneDirector | Received as pay | 1,695 | - |
| May 23, 2026 | Brown Brian LeeChief Financial Officer | Received as pay | 3,750 | - |
| May 23, 2026 | Brown Brian LeeChief Financial Officer | Other change | 1,350 | $6.8K |
Who owns CODX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 96,860 shares in total, about $26.9K at the last price.
| Holder | Shares |
|---|---|
| Egan Dwight HChief Executive Officer, Director | 27,893 |
| Brown Brian LeeChief Financial Officer | 22,379 |
| Murphy Edward L.Director | 11,084 |
| Serbin Richard SDirector | 10,751 |
| Durenard EugeneDirector | 10,668 |
| Nelson James BDirector | 10,668 |
| Abbott Richard DavidPresident | 3,417 |
Questions about CODX
What does Co-Diagnostics, Inc. do?
Co-Diagnostics, Inc. is a company in the Health care sector, listed on NASDAQ as CODX. Its shares trade on NASDAQ under the ticker CODX.
What is Co-Diagnostics, Inc.'s net worth?
Co-Diagnostics, Inc. has a market value (market cap) of $1.7M at the latest share price, and shareholders' equity of $12.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Co-Diagnostics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $47.1M on revenue of $721.4K.
How much revenue does Co-Diagnostics, Inc. make?
Over the twelve months to June 30, 2026 Co-Diagnostics, Inc. reported revenue of $721.4K. That is 28.1% less than a year earlier.
When did Co-Diagnostics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from October 5, 2026.
When is Co-Diagnostics, Inc.'s next earnings report?
Co-Diagnostics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CODX with
Follow CODX
Get an email when Co-Diagnostics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Co-Diagnostics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.